"LinXis’ linker-payload manufacturing technology published in Green Chemistry"

Read more


Our mission is to create targeted therapeutics that are effective, safe, and affordable.

A small number of antibody-drug conjugates have thus far been approved for human use, confirming that the targeted drug concept is viable. Practically however, they fail to reach many patients in need. On the one hand, this is due to their cost - their complex development and manufacturing processes make for a very high price. On the other hand, this is due to their disappointing safety and efficacy.

The goal of LinXis is to deliver on the initial promise of targeted therapeutics - by creating these medicines at low development- and manufacturing cost, with a favorable safety and efficacy profile, and for diseases that represent a world-wide and unmet medical need.

LinXis operates in alignment with the United Nations Sustainable Development Goals.